L3VLUP
ProSign in

AVTR · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

AVTRVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • AVTR
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterAVTRVRTX
Q3 202022 holders, $2.7bn31 holders, $21.9bn
Q4 202021 holders, $4.2bn30 holders, $18.4bn
Q1 202115 holders, $4.2bn31 holders, $15.4bn
Q2 202112 holders, $5.2bn30 holders, $12.7bn
Q3 202117 holders, $6.3bn35 holders, $10.1bn
Q4 202116 holders, $6.6bn28 holders, $12.4bn
Q1 202222 holders, $5.5bn23 holders, $16.1bn
Q2 202220 holders, $5.4bn25 holders, $18.1bn
Q3 202223 holders, $2.2bn22 holders, $18.4bn
Q4 202220 holders, $2.0bn28 holders, $18.4bn
Q1 202316 holders, $1.5bn26 holders, $21.4bn
Q2 202314 holders, $1.4bn27 holders, $24.7bn
Q3 202318 holders, $1.9bn33 holders, $24.3bn
Q4 202314 holders, $3.0bn32 holders, $28.6bn
Q1 202416 holders, $3.1bn31 holders, $29.8bn
Q2 202413 holders, $2.1bn29 holders, $33.4bn
Q3 20249 holders, $2.6bn27 holders, $33.5bn
Q4 202411 holders, $2.8bn26 holders, $28.5bn
Q1 202510 holders, $2.2bn21 holders, $35.4bn
Q2 202510 holders, $2.0bn21 holders, $32.3bn
Q3 202510 holders, $1.8bn22 holders, $25.9bn
Q4 20257 holders, $1.8bn26 holders, $31.8bn
Q1 20269 holders, $1.3bn25 holders, $31.8bn
Q2 20265 holders, $1.5bn26 holders, $34.6bn
AVTR

Avantor Inc

Holders
14
Reported value
$3.0bn
Buyers
9
Sellers
9

Breadth 0 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
32
Reported value
$28.6bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 39 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only AVTR (7)

Dodge & Cox, ExodusPoint Capital Management LP, First Eagle Investment Management LLC, Moore Capital Management LP, Point72 Asset Management LP, Soros Fund Management LLC, Walleye Capital LLC

Only VRTX (25)

Acadian Asset Management LLC, AQR Capital Management LLC, ARK Investment Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Farallon Capital Management LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Man Group PLC, Marshall Wace LLP, Maverick Capital Ltd, MFS Investment Management, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →